Abstract
A series of novel 4-isochromanone compounds bearing N-benzyl pyridinium moiety were designed and synthesized as acetylcholinesterase (AChE) inhibitors. The biological evaluation showed that most of the target compounds exhibited potent inhibitory activities against AChE. Among them, compound 1q possessed the strongest anti-AChE activity with an IC50 value of 0.15 nm and high AChE/BuChE selectivity (SI > 5,000). Moreover, compound 1q had low toxicity in normal nerve cells and was relatively stable in rat plasma. Together, the current finding may provide a new approach for the discovery of novel anti-Alzheimer's disease agents.
Keywords:
4-isochromanone skeleton; Alzheimer's disease; acetylcholinesterase inhibitors; benzyl pyridine.
© 2017 John Wiley & Sons A/S.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Acetylcholinesterase* / metabolism
-
Alzheimer Disease / drug therapy
-
Alzheimer Disease / metabolism
-
Alzheimer Disease / pathology
-
Animals
-
Cell Line, Tumor
-
Cholinesterase Inhibitors* / chemical synthesis
-
Cholinesterase Inhibitors* / chemistry
-
Cholinesterase Inhibitors* / pharmacology
-
GPI-Linked Proteins / antagonists & inhibitors
-
GPI-Linked Proteins / metabolism
-
Phenazopyridine* / analogs & derivatives
-
Phenazopyridine* / chemical synthesis
-
Phenazopyridine* / chemistry
-
Phenazopyridine* / pharmacology
-
Piperidones* / chemical synthesis
-
Piperidones* / chemistry
-
Piperidones* / pharmacology
-
Rats
Substances
-
Cholinesterase Inhibitors
-
GPI-Linked Proteins
-
Piperidones
-
Acetylcholinesterase
-
Ache protein, rat
-
Phenazopyridine